Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for Acute Respiratory Distress Syndrome (ARDS)
IRCT20231017059748N3Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Dec 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of baricitinib in acute respiratory distress syndrome (ARDS), sponsored by Tabriz University of Medical Sciences. Started Dec 2023; status: completed.
02
Drugs
baricitinib
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on IRCT20231017059748N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231017059748N3.